So sánh mù đôi giữa Lansoprazole 15 mg, Lansoprazole 30 mg và placebo trong việc duy trì bệnh loét dạ dày đã được chữa khỏi

Ihamaki T, Varis K, Siurela M: Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol 14:801 - 812, 1979 Kurata JH, Haile BM: Epidemiology of peptic ulcer disease. Clin Gastroenterol 13:289 - 305, 1984 Kurata JH, Nogowa AN, Abbey DE, Petersen F: A prospective study of risk for peptic ulcer disease in Seventh-Day Adventist. Gastroenterology 102:902 - 909, 1992 Bonnevie O: The incidence of duodenal ulcer in Copenhagen County. Scand J Gastroenterol 10:385 - 393, 1975 Bonnevie O: The incidence of gastric ulcer in Copenhagen County. Scand J Gastroenterol 10:231 - 239, 1975 School I-M, Mellstrom D, Oden A, Ytterberg B-O: Incidence of peptic ulcer disease in Gothenburg 1985. Br Med J 299:1131 - 1134, 1989 Jaszewski R, Calzada R, Dhar R: Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin. Dig Dis Sci 34:1361 - 1364, 1989 Collins AJ, Davies J, Dixon AS: A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol 27:106 - 109, 1988 Tytgat GNJ, Rauws EAJ: Campylobacter pyloriand its role in peptic ulcer disease. Gastroenterol Clin North Am 19:183 - 196, 1990 Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, Baskin WN, MacKercher PA, Hewett J: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91:517 - 520, 1979 Penston JG, Wormsley KG: Review article: Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 6:3 - 29, 1992 Soll AH: Gastric, duodenal, and stress ulcer. InGastrointestinal Disease: Pathophysiology/Diagnosis/Management. M Sleisenger, J Fordtran (eds). Philadelphia, Saunders, 1993, pp 580 - 679 Taha AS, Hudson N, Hawkey CJ, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435 - 1439, 1996 Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T: A controlled study of ranitidine for the prevention of recurre nt hemorrhage from duodenal ulcer. N Engl J Med 330:382 - 386, 1994 Holt S, Howden CW: Omeprazole: Overview and opinion. Dig Dis Sci 36:385 - 393, 1991 Nagaya H, Satoh H, Maki Y: Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289 - 1295, 1989 Sachs G, Shin JM, Besancon M, Prinz C: The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 7(suppl 1):4 - 12, 29 - 31, 1993 Tolman KG, Sanders SW, Buchi KN: Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 106(suppl 4):A172, 1994 Müller P, Dammann HG, Leucht U, Simon B: Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 3:193 - 198, 1989 Takemoto T, Namiki M, Goto Y: Clinical evaluation of lansoprazole (AG-1749) for gastric ulcer: A multicenter doubleblind comparison with famotidine. Rinsho Seijinbyo 21:327 - 345, 1991 Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, Sjostedt S, Smith PM, Stig R, Wormsley RG: Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 8:215 - 220, 1994 Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud JC, Dupas JL, Bigard MA, Vervae rd JC: Treatme nt of gastric ulcer with lansoprazole or ranitidine: A multicentre clinical trial. Aliment Pharmacol Ther 8:119 - 122, 1994 Florent C, Forestier M, Joubert-Collin M: Lansoprazole versus omeprazole: Efficacy and safety in acute gastric ulcer. Gastroente-rology 104:A80, 1993 Tielemans Y, Hakanson R, Sundler F, Willems G: Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology 96:723 - 729, 1989 Misawa T, Chijiiwa Y, Imazono Y: Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res 122:175 - 189, 1991 Ogoshi K, Kato T, Saito S: Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin leve ls and gastric mucosal ECL cell density. Yakuri Chiryo 19:933 - 946, 1991 Larsson H, Carlsson E, Hakanson R, Mattsson H, Nilsson G, Seensalu R, Wallmark B, Sundler F: Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology 95:1477 - 1486, 1988 Brunner G, Arnold R, Hennig U, Fuchs W: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 7(suppl 1):51 - 55, 1993 Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Grimelius L, Havu N: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41:185 - 200, 1988 Sharma B, Axelson M, Pounder RE, et al: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1:67 - 76, 1987 Karnes WE, Berlin RG, Maxwell V, et al: Prolonged inhibition of acid secretion causes hypergastrinaemia without altering pH inhibition of gastrin release in humans. Aliment Pharmacol Ther 4:443 - 456, 1990